Noncoding RNA, ncRNA-a3, Epigenetically Regulates TAL1 Transcriptional Program During Erythropoiesis
- PMID: 40211453
- PMCID: PMC12042867
- DOI: 10.1080/10985549.2025.2482079
Noncoding RNA, ncRNA-a3, Epigenetically Regulates TAL1 Transcriptional Program During Erythropoiesis
Abstract
Hematopoietic transcription is a combinatorial control of transcription factors, chromatin modifiers, and non-coding RNAs. TAL1 is a critical regulator of normal and malignant hematopoiesis. However, mechanism underlying regulation of TAL1 activity during erythropoiesis versus leukemogenesis remains elusive. Here, we showed that an enhancer RNA, ncRNA-a3 transcribed from TAL1 + 51Kb-enhancer, is positively correlated with TAL1 locus chromatin accessibility and transcription, and required for TAL1 activation during EPO-induced erythropoiesis. Loss of ncRNA-a3 in CD34+ hematopoietic stem and progenitor cells leads to reduction of TAL1 transcription, followed by impaired terminal erythroid differentiation. The effect of ncRNA-a3 loss on erythroid differentiation is partially rescued by overexpression of Tal1 cDNA, suggesting an important role of ncRNA-a3/TAL1 regulatory axis in erythropoiesis. Mechanistically, ncRNA-a3 regulates long-range chromatin interactions between +51Kb erythroid-specific enhancer, promoter and other regulatory elements in the TAL1 locus to maintain the erythroid interaction hub. By facilitating the binding and recruitment of p300/BRG1 to the TAL1 locus, ncRNA-a3 promotes chromatin accessibility in the TAL1 locus and activates TAL1 transcription program, including subsequent epigenetic and transcriptional activation of erythroid-specific TAL1 target genes. Our study reveals a novel role for ncRNA-a3 in TAL1 dependent erythropoiesis and establishes a new mode of ncRNA-a3 action in TAL1 transcriptional activation.
Keywords: TAL1 oncogene; chromatin structure; eRNA; erythropoiesis; gene regulation.
Conflict of interest statement
CONFLICT OF INTEREST
Authors do not have any conflict of interest
Similar articles
-
ID3 promotes erythroid differentiation and is repressed by a TAL1-PRMT6 complex.J Biol Chem. 2025 Feb;301(2):108119. doi: 10.1016/j.jbc.2024.108119. Epub 2024 Dec 22. J Biol Chem. 2025. PMID: 39716491 Free PMC article.
-
Transcription Factor TAL1 in Erythropoiesis.Adv Exp Med Biol. 2024;1459:243-258. doi: 10.1007/978-3-031-62731-6_11. Adv Exp Med Biol. 2024. PMID: 39017847 Review.
-
Aberrant TAL1 activation is mediated by an interchromosomal interaction in human T-cell acute lymphoblastic leukemia.Leukemia. 2014 Feb;28(2):349-61. doi: 10.1038/leu.2013.158. Epub 2013 May 23. Leukemia. 2014. PMID: 23698277 Free PMC article.
-
FUSE binding protein 1 (FUBP1) expression is upregulated by T-cell acute lymphocytic leukemia protein 1 (TAL1) and required for efficient erythroid differentiation.PLoS One. 2019 Jan 17;14(1):e0210515. doi: 10.1371/journal.pone.0210515. eCollection 2019. PLoS One. 2019. PMID: 30653565 Free PMC article.
-
Oncogenic transcriptional program driven by TAL1 in T-cell acute lymphoblastic leukemia.Int J Hematol. 2019 Jan;109(1):5-17. doi: 10.1007/s12185-018-2518-z. Epub 2018 Aug 25. Int J Hematol. 2019. PMID: 30145780 Review.
References
-
- Homminga I, Pieters R, Langerak AW, de Rooi JJ, Stubbs A, Verstegen M, Vuerhard M, Buijs-Gladdines J, Kooi C, Klous P, et al. Integrated transcript and genome analyses reveal nkx2-1 and mef2c as potential oncogenes in t cell acute lymphoblastic leukemia. Cancer Cell. 2011;19:484–497. doi: 10.1016/j.ccr.2011.02.008. - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous